NRIX Nurix Therapeutics Inc
Price (delayed)
$13.19
Market cap
$1B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.88
Enterprise value
$918.35M
Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer
Highlights
NRIX's equity has surged by 163% year-on-year and by 40% since the previous quarter
NRIX's quick ratio has surged by 92% year-on-year and by 23% since the previous quarter
NRIX's debt is down by 8% year-on-year but it is up by 4.3% since the previous quarter
The net income has declined by 34% year-on-year and by 9% since the previous quarter
The revenue has contracted by 29% YoY and by 3.3% from the previous quarter
Key stats
What are the main financial stats of NRIX
Market
Valuations
Earnings
Shares outstanding
75.89M
Market cap
$1B
Enterprise value
$918.35M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.77
Price to sales (P/S)
16.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.84
Revenue
$54.55M
Gross profit
$54.55M
Operating income
-$213.03M
Net income
-$193.57M
EBIT
-$193.3M
EBITDA
-$176.87M
Free cash flow
-$181.86M
Per share
Balance sheet
Liquidity
EPS
-$2.88
EPS diluted
-$2.88
Free cash flow per share
-$2.71
Book value per share
$7.44
Revenue per share
$0.81
TBVPS
$9.97
Total assets
$669.34M
Total liabilities
$142.35M
Debt
$28.3M
Equity
$526.99M
Working capital
$523.53M
Debt to equity
0.05
Current ratio
6.46
Quick ratio
6.37
Net debt/EBITDA
0.47
Margins
Efficiency
Dividend
EBITDA margin
-324.2%
Gross margin
100%
Net margin
-354.9%
Operating margin
-390.5%
Return on assets
-38.6%
Return on equity
-53.6%
Return on invested capital
-55.6%
Return on capital employed
-33.7%
Return on sales
-354.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NRIX stock price
How has the Nurix Therapeutics stock price performed over time
Intraday
-9.28%
1 week
-6.12%
1 month
-24.93%
1 year
-8.91%
YTD
-29.99%
QTD
-29.99%
Financial performance
How have Nurix Therapeutics's revenue and profit performed over time
Revenue
$54.55M
Gross profit
$54.55M
Operating income
-$213.03M
Net income
-$193.57M
Gross margin
100%
Net margin
-354.9%
Nurix Therapeutics's operating margin has shrunk by 94% YoY and by 14% QoQ
NRIX's net margin has dropped by 90% year-on-year and by 13% since the previous quarter
The operating income has declined by 37% year-on-year and by 10% since the previous quarter
The net income has declined by 34% year-on-year and by 9% since the previous quarter
Growth
What is Nurix Therapeutics's growth rate over time
Valuation
What is Nurix Therapeutics stock price valuation
P/E
N/A
P/B
1.77
P/S
16.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.84
NRIX's EPS is down by 9% year-on-year
NRIX's equity has surged by 163% year-on-year and by 40% since the previous quarter
The stock's price to book (P/B) is 45% less than its last 4 quarters average of 3.2 and 39% less than its 5-year quarterly average of 2.9
The stock's price to sales (P/S) is 37% less than its 5-year quarterly average of 25.9 and 23% less than its last 4 quarters average of 21.0
The revenue has contracted by 29% YoY and by 3.3% from the previous quarter
Efficiency
How efficient is Nurix Therapeutics business performance
NRIX's return on sales has dropped by 90% year-on-year and by 13% since the previous quarter
The ROE has grown by 15% from the previous quarter and by 10% YoY
NRIX's return on invested capital is up by 10% since the previous quarter and by 7% year-on-year
NRIX's return on assets is up by 8% since the previous quarter and by 7% year-on-year
Dividends
What is NRIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NRIX.
Financial health
How did Nurix Therapeutics financials performed over time
NRIX's quick ratio has surged by 92% year-on-year and by 23% since the previous quarter
NRIX's current ratio has surged by 90% year-on-year and by 22% since the previous quarter
NRIX's debt is 95% smaller than its equity
NRIX's equity has surged by 163% year-on-year and by 40% since the previous quarter
The debt to equity has dropped by 67% year-on-year and by 29% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.